complications webinar header - Davis Phinney Foundation

 

Depression, anxiety, cognitive decline, psychosis and impulse control disorders can be common in people with Parkinson’s and have a profound effect on quality of life. It’s important as a person living with Parkinson’s or as a Parkinson’s care partner to become more educated about these conditions, how they may affect the goal of living well and ways to manage and mitigate them.

In this webinar on psychiatric and cognitive complications in Parkinson’s, Dr. Weintraub will address:

  • Parkinson’s progression and signs to look out for
  • Depression and mood disorders
  • The difference between Parkinson’s depression and general depression
  • The correlation between mood, motor function and Levodopa levels
  • Parkinson’s Disease Psychosis (PDP)
  • Cognitive impairment and dementia and common cognitive profiles of those with Parkinson’s
  • Impulse control disorders (ICDs) and related behaviors
  • Anxiety
  • Sleep disorders
  • And much more

Sign Up to Attend the Live Webinar:

(If you can’t make it live, be sure to register anyway so we can send you the recording as soon as it’s available.)

 

Your Instructor for the Webinar

 

Dr. Daniel Weintraub is Assistant Professor of Psychiatry at the University of Pennsylvania and Fellow at the University of Pennsylvania Institute of Aging. He completed medical, psychiatry residency, and geriatric psychiatry fellowship training at the University of Maryland. His areas of research interest include the psychiatric and cognitive complications of Parkinson’s disease. He is current recipient of a 5-year Career Development Award (K23) from the National Institute of Mental Health (NIMH) titled “Depression Diagnosis and Treatment in Parkinson Disease.” In addition, he is currently Coordinating Investigator for a multi-site international industry-sponsored study of the frequency and correlates of impulse control disorders in PD. Dr. Weintraub has also served on three Movement Disorder Society (MDS) task forces to revise and make recommendations for the assessment of non-motor symptoms in Parkinson’s disease, and is a member of the Scientific Review Committee of the Parkinson Study Group.